Clinical trial
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
NCT00405808 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00405808 |
|---|---|
| Title | Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose |
| Official title | A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities |
| Acronym | PRADO |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | Rimonabant, Placebo |
| Enrollment | 2,666 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Nov 30, 2006 |
| Last update posted | Jan 26, 2011 |
| Countries | Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Egypt, Finland, France, Greece, Hungary and 15 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: